These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30381673)

  • 21. Duloxetine: a review of its pharmacology and use in chronic pain management.
    Bellingham GA; Peng PW
    Reg Anesth Pain Med; 2010; 35(3):294-303. PubMed ID: 20921842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of smoking on the serum level of duloxetine.
    Fric M; Pfuhlmann B; Laux G; Riederer P; Distler G; Artmann S; Wohlschläger M; Liebmann M; Deckert J
    Pharmacopsychiatry; 2008 Jul; 41(4):151-5. PubMed ID: 18651344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BDNF level in the rat prefrontal cortex increases following chronic but not acute treatment with duloxetine, a dual acting inhibitor of noradrenaline and serotonin re-uptake.
    Mannari C; Origlia N; Scatena A; Del Debbio A; Catena M; Dell'agnello G; Barraco A; Giovannini L; Dell'osso L; Domenici L; Piccinni A
    Cell Mol Neurobiol; 2008 May; 28(3):457-68. PubMed ID: 18172756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant.
    Kasahara T; Ishigooka J; Nagata E; Murasaki M; Miura S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Feb; 16(1):25-31. PubMed ID: 8640460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.
    Hunziker ME; Suehs BT; Bettinger TL; Crismon ML
    Clin Ther; 2005 Aug; 27(8):1126-43. PubMed ID: 16199241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
    Bymaster FP; Lee TC; Knadler MP; Detke MJ; Iyengar S
    Curr Pharm Des; 2005; 11(12):1475-93. PubMed ID: 15892657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The development of new antidepressants: focus on duloxetine and escitalopram.
    Huffman JC; Perlis RH
    Harv Rev Psychiatry; 2003; 11(1):30-6. PubMed ID: 12866739
    [No Abstract]   [Full Text] [Related]  

  • 28. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidepressant behavioral effects of duloxetine and fluoxetine in the rat forced swimming test.
    Ciulla L; Menezes HS; Bueno BB; Schuh A; Alves RJ; Abegg MP
    Acta Cir Bras; 2007; 22(5):351-4. PubMed ID: 17923954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent episodes of serotonin-reuptake inhibitor-mediated hyponatremia in an elderly patient.
    Stovall R; Brahm NC; Crosby KM
    Consult Pharm; 2009 Oct; 24(10):765-8. PubMed ID: 20017411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms for the inhibition of genital vascular responses by antidepressants in a female rabbit model.
    Angulo J; Cuevas P; Cuevas B; Gupta S; Sáenz de Tejada I
    J Pharmacol Exp Ther; 2004 Jul; 310(1):141-9. PubMed ID: 15034084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain.
    Rueter LE; Kasamo K; de Montigny C; Blier P
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jun; 357(6):600-10. PubMed ID: 9686935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression.
    Sindhu P; Kumar S; Iqbal B; Ali J; Baboota S
    J Psychiatr Res; 2018 Apr; 99():83-95. PubMed ID: 29427845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a place for duloxetine?
    Drug Ther Bull; 2007 Apr; 45(4):29-32. PubMed ID: 17451072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter.
    Troelsen KB; Nielsen EØ; Mirza NR
    Psychopharmacology (Berl); 2005 Oct; 181(4):741-50. PubMed ID: 16032412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Desvenlafaxine and neuropathic pain: additional clinical benefits of a second generation serotonin-noradrenaline reuptake inhibitor].
    Alcantara-Montero A
    Rev Neurol; 2017 Mar; 64(5):219-226. PubMed ID: 28229443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex.
    Millan MJ; Brocco M; Veiga S; Cistarelli L; Melon C; Gobert A
    Eur J Pharmacol; 1998 Jan; 341(2-3):165-7. PubMed ID: 9543235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prescribing update: why choose duloxetine for depression?
    Tobin ML
    Issues Ment Health Nurs; 2007 Jan; 28(1):117-20. PubMed ID: 17130011
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of novel antidepressant drugs on mesenchymal stem cell physiology.
    Ferroni L; Gardin C; Bellin G; Vindigni V; Pavan C; Zavan B
    Biomed Pharmacother; 2019 Jun; 114():108853. PubMed ID: 30986624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.